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Abstract
Protein ubiquitination plays an important role in the regulation of almost every aspect of eukaryotic cellular function;
therefore, its destabilization is often observed in most human diseases and cancers. Consequently, developing inhibitors of
the ubiquitination system for the treatment of cancer has been a recent area of interest. Currently, only a few classes of
compounds have been discovered to inhibit the ubiquitin-activating enzyme (E1) and only one class is relatively selective in
E1 inhibition in cells. We now report that Largazole and its ester and ketone analogs selectively inhibit ubiquitin conjugation
to p27
Kip1 and TRF1 in vitro. The inhibitory activity of these small molecules on ubiquitin conjugation has been traced to
their inhibition of the ubiquitin E1 enzyme. To further dissect the mechanism of E1 inhibition, we analyzed the effects of
these inhibitors on each of the two steps of E1 activation. We show that Largazole and its derivatives specifically inhibit the
adenylation step of the E1 reaction while having no effect on thioester bond formation between ubiquitin and E1. E1
inhibition appears to be specific to human E1 as Largazole ketone fails to inhibit the activation of Uba1p, a homolog of E1 in
Schizosaccharomyces pombe. Moreover, Largazole analogs do not significantly inhibit SUMO E1. Thus, Largazole and select
analogs are a novel class of ubiquitin E1 inhibitors and valuable tools for studying ubiquitination in vitro. This class of
compounds could be further developed and potentially be a useful tool in cells.
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Introduction
In humans, protein ubiquitination is a dynamic process,
depending on a tightly regulated balance between the activity of
two ubiquitin-activating enzymes (E1s), approximately 40 ubiqui-
tin-conjugating enzymes (E2s), and hundreds of ubiquitin ligases
(E3s). Protein ubiquitination and subsequent degradation regulates
almost every aspect of eukaryotic cellular function including cell
cycle regulation, endocytosis, signal transduction, apoptosis, DNA
damage repair, transcriptional regulation, and many others [1].
Hershko and coworkers discovered that ubiquitin covalently
modified proteins prior to their degradation in rabbit reticulocyte
lysates and characterized the reaction mechanism [2]. They first
described the ubiquitin-activating enzyme, E1, that carries out the
ATP-dependent activation of the C-terminal glycine residue of
ubiquitin prior to ligation. In the first step of the E1 activation, the
enzyme forms a complex with ubiquitin and ATP and catalyzes
the adenylation of ubiquitin and successive release of pyrophos-
phate (PPi). During the second step, a thioester bond is formed
between the C-terminus of ubiquitin and E1, subsequently
releasing adenosine monophosphate (AMP). In the final step of
E1 activation, additional ATP and ubiquitin are recruited to the
adenylation site, generating a fully loaded E1 carrying two
molecules of ubiquitin. The activated ubiquitin is then transferred
to a cysteine in the active site of ubiquitin carrier protein E2, also
via thiol ester linkage. Some E2 enzymes transfer ubiquitin to
acceptor proteins directly, whereas other E2s require additional
substrate binding proteins known as ubiquitin ligases or E3s
[3,4].Through this mechanism, ubiquitin is attached to proteins by
isopeptide linkages between the C-terminal Gly76 of ubiquitin and
the e-amino groups of lysine residues present in substrate proteins.
In addition, linkages between Lys48 of one ubiquitin and the C-
terminal Gly76 of another ubiquitin ultimately form polyubiquitin
chains [5]. Once polyubiquitinated, proteins are targeted by the
26S proteasome for degradation.
In many human cancers, the ubiquitination system is often
destabilized. For example, the cyclin-dependent kinase inhibitor
p27 is mainly regulated at the protein level and is excessively
degraded in approximately 50% of all human cancers [6,7].
Furthermore, expression of p27 is primarily controlled by
polyubiquitination via the SCF
Skp2 E3 ubiquitin ligase and
subsequent proteasomal degradation [8]. The SCF
Skp2 is a
cullin-RING ligase (CRL), which is comprised of RING-box
protein I (Rbx1), scaffold protein Cul1, linker protein Skp1, and F-
box protein Skp2 [9]. In order for the ligase to function, Cul1 must
first be covalently modified by NEDD8, an ubiquitin-like protein
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result from decreased polyubiquitination by inhibiting the
neddylation of Cul1 or one of the enzymes required for
ubiquitination.
Given that ubiquitination influences many cellular functions,
malfunctions in the pathway play a role in the pathogenesis of
human neurodegenerative disorders such as Parkinson’s, Alzhei-
mer’s and Huntington’s diseases, as well as cancer. Inhibiting
components of the ubiquitination system seems to be an avenue of
therapeutic development with clinical applications [13,14]. For
example, each E3 ligase targets a small number of proteins for
ubiquitination, which makes it a potential target for highly specific
inhibitors that have few side effects. There has, however, been little
success in developing inhibitors of specific E3 ligases until recently
[14,15]. Also, proteasome-inhibiting compounds have been a
target of interest and were originally developed as tools for probing
its proteolytic function [16,17]; however, these inhibitors were
considered as possible cancer therapeutics after it was observed
that they induced apoptosis in leukemic cell lines [18–20].
Although inhibiting the proteasome would nonspecifically inhibit
the entire ubiquitination system, the proteasome inhibitor
Bortezomib has fared surprisingly well in clinical trials and is
now FDA approved for the treatment of relapsed and refractory
myeloma and mantle cell lymphoma [19]. Therefore, inhibitory
compounds of the ubiquitin system, whether they are specific or
nonspecific, have the potential to be important therapeutics for the
treatment of cancer.
In January 2008, the Leusch group at the University of Florida
identified a natural product they named Largazole, which was
isolated from cyanobacteria of the Symploca genus. They examined
the compound for cytoxicity against cancer cells and observed
remarkable antiproliferative activity in transformed mammary
epithelial cells. In addition, they showed that Largazole preferen-
tially targets cancer cells over normal cells, which makes this
marine substance an important synthetic target as well as a
potentially valuable cancer chemotherapeutic. Remarkably, the
structure consists of several unusual features, such as a 16-
membered macrocycle containing a 4-methylthiazoline fused to a
thiazole ring and an octanoic thioester side chain, a unit rarely
found in natural products. [21]. Also, Leusch and co-workers first
reported the total synthesis of Largazole and determined that the
molecular basis for its anticancer activity is HDAC inhibition
[21,24]. Numerous analogs of Largazole have been generated in
efforts to understand the structure-activity relationship, and it has
been determined that the thioester moiety is required for HDAC
inhibition [21–32]. Here, we report in vitro mechanistic studies that
reveal a potential role of Largazole as an antagonist of the
ubiquitin-activating enzyme E1. In contrast to HDAC inhibition,
ketone and ester analogs of Largazole can actively block the
ligation of ubiquitin onto E1, indicating a differential mode of
inhibitory activity since the formation of a thiol metabolite is
indispensible for E1 inhibition. More explicitly, Largazole’s
presence negatively affected the formation of ubiquitin adenylate,
which we monitored through nucleotide exchange assay.
Materials and Methods
Construction of Kip16, a GFP-p27 Expressing Cell Line
Mink lung epithelial cells expressing GFP-p27 were generated
by retroviral-mediated gene transfer. pBabe-GFP-p27 amphotro-
pic virus was made by cotransfecting pBabe-GFP-p27-Puro with
pCL-Ampho in 293T cells. Viral supernatant was collected and
used to infect mink lung epithelial cell line Mv 1 Lu (CCL-64) from
ATCC in the presence of 8 mg/ml polybrene. Puromycin was
added at 5 mg/ml and stable clones were selected. Each clone was
subcultured and tested for GFP-p27 expression in the presence or
absence of 10 mM MG132 (Calbiochem, Darmstadt, Germany)
for 24 hours. Clones expressing high levels of GFP in the presence
of MG132 but low or unndetectable GFP in its absence were
expanded. Immunoblotting using an anti-p27 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) was used to confirm the
expression of the GFP-p27 fusion protein and stabilization of GFP-
p27 upon MG132 treatment. One of the clones used for all
subsequent studies was named Kip16.
Largazole Treatment of Kip 16 cells
Total synthesis of Largazole and Largazole analogs is described
in [24] within the supporting information (including copies of
spectra of all compounds) and is available at http //pubs.acs.org.
Kip16 cells were seeded into 96-well flat clear-bottomed plates at
40,000 cells/well in 100 ml medium and incubated overnight at
37uC in a humidified 5% CO2 atmosphere. Largazole was then
added to final concentrations ranging from 1 mM to 1 nM in
300 ml of fresh medium. 0.3% DMSO and 1 mM of MG132 were
used as negative and positive controls, respectively. After 24 hours
of incubation, the medium was removed, the cells were washed
twice with phosphate-buffered saline (PBS), and the cells were
fixed with 4% paraformaldehyde in PBS for 15 minutes and stored
at 4uC for microscopy evaluation. Cells were visualized with a
GFP filter set using a 106 objective on an Eclipse TE2000-S
(Nikon, Melville, NY) equipped with a Photometrics camera
(Roper Scientific, Tucson, AZ).
UBA1 and His-cdc34 Purification
Human ubiquitin E1 (UBA1) was expressed with an N-terminal
GST tag fusion by means of recombinant baculovirus expression
in Hi5 insect cells using the pFastBacHTA vector (Invitrogen,
Carlsbad, CA). The cells were lysed by sonication in the presence
of protease inhibitors in a buffer containing 200 mM NaCl,
50 mM Tris-HCl pH 7.5, 1% NP40, 1 mM DTT, and 1 mM
EDTA. Cleared lysate was incubated with glutathione beads
(Amersham, Sweden) for one hour at 4uC. After three washes with
lysis buffer, untagged E1 was produced by thrombin cleavage. The
protein solution was passed through a S200 gel filtration column
(Amersham, Sweden), and UBA1 concentration and purity was
evaluated by SDS-PAGE and Coomassie Blue gel staining. The
purity was generally greater than 90% and purified UBA1 was
aliquoted and stored at 280uC after quick freezing in liquid
nitrogen. N-terminal hexahistidine (His)-tagged human Cdc34 was
cloned into the pQE-30 vector (Qiagen, Valencia, CA) and
expressed in Eschericia coli. His-cdc34 was purified by Ni-NTA
chromatography followed by ion exchange and size-exclusion
chromatography. The purity and concentration of His-cdc34 were
determined by SDS-PAGE analysis.
In Vitro Ubiquitination of p27 and Trf1
Mouse p27, cloned into pCS2, was translated in vitro in a
reticulocyte lysate system (Promega, Madison, WI) in the presence
of [
35S]-labeled methionine. p27 was phosphorylated by purified
recombinant Cdk2-CyclinE as outlined by Ungermannova et al
[33]. 5 ml of the phosphorylation reaction was incubated with a
ubiquitin mixture containing 100 nM UBA1, 200 nM His-cdc34,
100 nM SCF
Skp2 E3 ligase complex, 50 nM Cks1, 10 mM
ubiquitin (Sigma Aldrich, St. Louis, MO), 10 mM methylated
ubiquitin (Boston Biochem, Cambridge, MA), 1 ml of energy
regeneration system (noted as 206ER and consisting of 10 mM
ATP, 20 mM Tris-HCl pH 7.4, 100 mM MgCl2, 200 mM
creatine phosphate, 2 mg/ml creatine phosphokinase, and 10%
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:glycerol) , 1 mM ubiquitin aldehyde, and 1 mM MG132 in a total
volume of 15 ml. The reaction was quenched after 30 minutes in a
30uC water bath by addition of 46 SDS sample buffer. The
products of ubiquitination were resolved by SDS-PAGE, destained
in a 45% methanol and 10% acetic acid solution in water, dried
and exposed overnight to a phosphoimager screen, and scanned
using a Typhoon scanner 9400 (GE Healthcare, Piscataway, NJ).
In vitro Trf1 ubiquitination was carried out as described in Zeng et
al [34]. Recombinant Trf1, labeled with [c-
33P]-ATP by CDK1-
CyclinB, was incubated with 0.5 mM UBA1, 5 mM UbcH5a,
1 mM SCF
Fbx4 E3 ligase complex, 5 mM ubiquitin, 100 mM
methylated ubiquitin, 1 mM ubiquitin aldehyde, and 1 ml2 0 6ER
for two hours at 30uC. Ubiquitinated Trf1 was analyzed by SDS-
PAGE followed by autoradiography.
E1/E2 Thioester Bond Formation Assay
40 nM ubiquitin E1 (UBA1) or 1 mM S. pombe E1 (Uba1p, gift
from Chris Lima) or 0.5 mM human SUMO E1 (Boston Biochem,
Cambridge, MA) were pre-incubated with 206ER at 30uC for
5 minutes in thioester reaction buffer (20 mM Tris pH 7.6,
50 mM NaCl, and 10 mM MgCl2). After 5 minutes, 1 mM
fluorescein-ubiquitin (Boston Biochem, U-590) was added to
initiate attachment of ubiquitin. All components were allowed to
react for another 5 minutes in a total volume of 5 ml. The reaction
was stopped with 10 ml of SDS-PAGE loading buffer, minus DTT,
and the proteins were resolved using 12% gels that were run on ice
to prevent the reduction of E1-ubiquitin due to the heat generated
during electrophoresis. Thioester bond formation was visualized
by scanning the gel using Typhoon scanner 9400 (GE Healthcare)
that was set to fluorescence mode (532 nM). When necessary
100 nM of E2 (Cdc34) was added after the E1 enzyme was pre-
charged with ATP. Serially diluted Largazole and its analogs were
incubated with the reagents as stated in the text. ImageJ was
utilized to quantify the fluorescence signal, and the dose response
curves were generated by nonlinear least regression analysis of
data using Prism (GraphPad, San Diego, CA).
[a-
32P]-AMP: [a-
32P]-ATP and [
32P]-PPi:[c-
32P]-ATP
Exchange Assays
The reaction mixture contained, in a final volume of 10 ml,
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2
(reaction assay buffer), 150 nM human ubiquitin E1 (UBA1),
100 mM ATP, 2 mM AMP, 1 mM[ a-
32P]- or [c-
32P]- ATP
(Perkin Elmer, Waltham, MA), 500 mM PPi (sodium salt). A total
of 5 mM ubiquitin was added to the mixture to initiate the
ATP:AMP exchange. After incubation at 30uC for 10 minutes, the
reactions were quenched with EDTA, and 0.5 ml aliquots of the
reaction mixtures were spotted on Baker-flexH thin layer
chromatography (TLC) polyethylenimine-modified cellulose plates
(J.T. Baker, Phillipsburg, NJ) and developed in filtered 0.34 M
potassium phosphate pH 7.0 for 20 minutes in a glass jar. The
TLC plates were allowed to air dry for 10 minutes, covered in
plastic wrap, and then exposed to a phosphoimager plate for 5–
10 minutes. The separation of radiolabeled nucleotides was
visualized using a Typhoon scanner 9400 (GE Healthcare,
Piscataway, NJ).
Results
Largazole stabilizes GFP-p27 expression in Kip16 cells
A hallmark of many advanced cancers is an excessive
degradation of the cyclin-dependent kinase inhibitor p27, which
is chiefly directed by SCF
Skp2-mediated ubiquitination. Hence,
stabilization of p27 degradation represents a rational approach in
cancer therapeutics. To identify small molecule inhibitors that can
stabilize p27Kip1, we performed a screen of ,3000 compounds
from NCI DTP diversity set along with several natural products in
our collection. For the cell-based screen, we generated a mink lung
epithelial cell line (Kip16) stably expressing p27 that was cloned in
frame with green fluorescent protein (GFP). The resulting N-
terminal GFP-p27 fusion, detectable by fluorescence microscopy,
was used to determine the levels of p27 expression upon treatment
of cells with the compound libraries in 96-well format. Much to
our surprise, the most potent hit that emerged from this screen was
the natural compound Largazole (L) (Figure 1), which was first
described by Luesch and coworkers [21] and subsequently
synthesized in several laboratories including ours [21,24–
26,29,30,32]. Largazole induced a robust and highly uniform
upregulation of GFP-p27 at concentrations as low as 1 nM
(Figure 2A). As expected, treatment with the proteasome inhibitor
MG132 is highly effective in prevention of p27 degradation. We
did not observe an increase in GFP-p27 expression upon
treatment with the vehicle DMSO. This result suggests that
Largazole can stabilize GFP-p27 expression in cultured cells.
Largazole and select analogs inhibit the in vitro
ubiquitination of p27 and Trf1
Before Largazole’s function as an inhibitor of histone deacety-
lase was revealed, our initial investigation into the mechanism of
this compound showed its ability to impede degradation of GFP-
p27 in Kip 16 cells. One way to stabilize p27 is to block its
ubiquitination. Hence we hypothesized that Largazole stabilizes
p27 by inhibiting the ubiquitination pathway [7,8]. One of the
downsides of cell-based assays is that the effects observed may be
attributed to the influence of multiple pathways. For example,
inhibiting the proteasome, elevating transcription of p27, or
inhibiting Cdk activity can also lead to an increase in p27
expression. To tease out the mechanism and action of Largazole
on p27 stabilization, we decided to test the effect of Largazole on
p27 ubiquitination in a fully reconstituted system in vitro [33,35].
To test if Largazole affects p27 ubiquitination in vitro, we added
Largazole to a p27 ubiquitin ligation reaction. As shown in
Figure 2C, adding Largazole significantly reduced polyubiquiti-
nated p27, suggesting that Largazole blocks p27 ubiquitination.
Since Largazole is known to be a histone deacetylase inhibitor and
has a thioester moiety that links an aliphatic chain to the core, we
decided to test whether inhibition of p27 degradation can be
linked to its histone deacetylase inhibitory activity. The structure-
activity relationship for Largazole is relatively well understood
[36]. Therefore we next tested a series of Largazole analogs
(Figure 1) to study the effect of structure-activity relationship on
p27 ubiquitination. To investigate this, Largazole ester (E),
Largazole ketone (K), Largazole macrocycle (M), and seco-
Largazole (S) were tested in an in vitro p27 ubiquitination assay
(Figure 2C). We also added the HDAC inhibitor Trichostatin A
(TSA), the structure of which can be found in Figure 1, to the assay
to determine whether or not other HDAC inhibitors affect p27
ubiquitination. We observed that Largazole (L), Largazole ketone
(K), and Largazole ester (E) inhibited the ligation of ubiquitin onto
p27; however, the M and S analogs and TSA failed to inhibit the
ubiquitination of p27 (Figure 2C). The fact that M had no
inhibitory activity highlights the role of the octanoyl chain in
hindering p27 polyubiquitination. Seco-Largazole (S) did not affect
p27 ubiquitination, indicating the importance of the topology of
the inhibitory compound. Furthermore, the result also suggests
that the thioester moiety of Largazole is not required for
inhibition, because the ketone and ester analogs were equally
potent in blocking p27 ubiquitination. In addition, E1 inhibition is
Largazole as a Novel E1 Inhibitor
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and ester fail to inhibit HDAC. Prior to ubiquitination, p27 is
phosphorylated by the Cdk2-CyclinE complex. We carried out an
in vitro p27 phosphorylation assay (as described in [33]) in the
presence of either DMSO or Largazole in order to test whether or
not the decrease in p27 ubiquitination was due to the inhibition of
the Cdk2-CyclinE complex. We observed that Largazole does not
inhibit the phosphorylation of p27 (Figure 2B); therefore, the
inhibition of p27-ubiquitin conjugation is due to an inhibition of
the ubiquitination process rather than phosphorylation step.
To study the specificity of largazole’s inhibition, we set up Trf1
in vitro polyubiquitination in the presence of varying concentrations
of largazole ester and found that E inhibited the ubiquitin
attachment in a dose-dependent manner (Figure 2D). Since
ubiquitination of both proteins was impeded, and given that both
reactions require different factors to execute it (p27 has to be
phosphorylated by CDK2-CyclinE while there is no requirement
for Trf1 phosphate addition, E2 for p27 is Cdc34, while Trf1
needs Ubc5Ha, SCFSkp2 ligase works with p27 while Fbx4 is the
substrate recognition subunit for Trf1) it was evocative that
largazole compounds stall a step that is common to both
polyubiquitination reactions.
Largazole and ester/keto analogs inhibit ubiquitin E1
activation
Since both p27 and Trf1 can be ubiquitinated in the presence
of UBA1, we hypothesized that the inhibitory activity of
Largazole is due to the deactivation of E1. To test this hypothesis,
we incubated Largazole and Largazole ester with recombinant
E1 prior to carrying out an in vitro thioester assay we described
previously [37]. In addition, we tested the active thiol form of
Largazole (T) for E1 inhibition. The presence of a fluorescence
signal in the thioester assay suggests the formation of E1-ubiquitin
adducts. The dose dependent decrease in fluorescence indicates
that Largazole and Largazole ester inhibit the formation of E1-
ubiquitin adducts (Fig. 3AC). The dose-response curves generated
(data not shown) suggest an IC50 of approximately 29 mM and
25 mM for Largazole and Largazole ester, respectively. Interest-
ingly, the active thiol form of Largazole (T) failed to inhibit E1
(Fig. 3G), suggesting again that the octanoyl residue is important
for inhibition.
Activated ubiquitin is normally transferred to ubiquitin
conjugating enzymes (E2). If E1 activity is inhibited, we expect
to see that defects in E1 activation should impair the attachment of
Figure 1. Chemical structures of Largazole, synthetic analogs, and Trichostatin A. Largazole (L) includes a substituted 4-methythiazoline
linearly fused to a thiazole, a 3-hydroxy-7-mercaptohept-4-enoic acid, a thioester moiety, and a hydrocarbon tail. Analogs include a substituted
ketone (K) and ester (E) in place of the thioester moiety, a macrocycle lacking the thioester moiety and hydrocarbon tail (M), an analog containing a
macrocycle broken at carbon-3 of the enoic acid (S), and a thiol analog lacking the thioester moiety (T). Trichostatin A (TSA) contains a hydroxamic
acid functional group.
doi:10.1371/journal.pone.0029208.g001
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included Cdc34, the E2 enzyme required for p27 ubiquitinaton, in
the E1 reaction mixture. As shown in Figure 3EF, in the presence
of ATP, fluorescent ubiquitin is transferred to Cdc34 indicated by
the presence of a fluorescent Cdc34 band on the gel. Upon
incubation with E1, Largazole or Largazole ester reduce the
amount of ubiquitin molecules that are transferred from E1 to E2
in a dose-dependent fashion (Fig. 3BD).
The decreased ubiquitin transfer could be attributed to either
E1 or E2 inhibition; therefore, we produced E1 precharged with
ubiquitin by incubating ATP and fluorescent ubiquitin for
15 minutes at room temperature followed by the addition of
Cdc34, which was preincubated with either Largazole or
Largazole ester. If either compound inhibits the transfer of
ubiquitin from E1 to E2, then we would observe a significant
decrease in Cdc34 fluorescence regardless of the order we added
the compounds. Interestingly, Largazole, preincubated with
Cdc34, fails to inhibit the transfer of ubiquitin from precharged
E1 at concentrations ,1 mM (Fig. 3E). Furthermore, in a similar
experiment, Largazole ester begins to inhibit the transfer of
ubiquitin from precharged E1 to Cdc34 at concentrations around
500 mM (Fig. 3F), although this concentration is significantly
above the IC50 of E1 inhibition. These results suggest that
Largazole and Largazole ester exhibit selectivity towards ubiquitin
E1. Also, this result suggests that either compound fails to promote
the hydrolysis of ubiquitin thioesters on precharged E1.
Largazole ketone inhibits the adenylation step of E1
activation
E1 forms an ubiquitin–adenylate intermediate during the
course of its catalytic cycle [3]. Thus the mechanism of ubiquitin
E1 activation can be studied by assaying ATP:PPi and ATP:AMP
exchanges [3]. Production of AMP in the [a-
32P]-AMP:[ a-
32P]-
ATP exchange assay guarantees that a thioester bond is formed
between E1 and ubiquitin, while the release of PPi, measured by
the [
32P]-PPi:[c-
32P]-ATP exchange assay, signals the formation
of ubiquitin adenylate. To further dissect the mechanism of
Largazole inhibition, two nucleotide exchange assays were
carried out in the presence of Largazole derivatives. For these
experiments we used Largazole ketone, which is similar to
Largazole and Largazole ester. From the results shown in
Figure 4, it is evident that the first two concentrations of
Largazole ketone (100 and 50 mM) inhibit ubiquitination of E1
similarly and were also inhibitory in both types of exchange
assays. The lack of a [
32P]-PPi signal suggests that the adenylation
step did not occur; consequently, ubiquitin could not be
transferred to the active site cysteine to trigger the release of
AMP. Both steps of the E1-catalyzed reactions can be measured
by the AMP:ATP exchange assay. The lack of an [a-
32P]-AMP
signal further suggests that the adenylation step is inhibited by
Largazole ketone. Thus Largazole or Largazole derivatives act on
the first step of ubiquitin activation pathway by blocking the
formation of ubiquitin-adenylate.
Figure 2. Largazole stabilizes p27 expression in Kip16 cells and inhibits p27 ubiquitination in vitro. (A) Fluorescent and corresponding
bright-field images of Kip16 cells treated with varying concentrations of Largazole (L). L treatment induces the expression of GFP-p27 in a dose-
dependent fashion. Addition of MG132 (1 mM) prevents the degradation of GFP-p27 via the ubiquitination and subsequent proteasomal degradation
pathway. The vehicle control, DMSO, has no effect on the reporter protein stabilization. (B) L fails to inhibit the phosphorylation of p27 by the Cdk2/
CyclinE complex compared to the positive control. L (250 mM, lane 3, and 125 mM, lane 4) was incubated with the Cdk2/CyclinE complex prior to the
autophosphorylation of Cdk2/CyclinE step. Phosphorylated-p27 was identified by protein standard. (C) L, K, and E reduce polyubiquitinated forms of
p27 while M and S have no inhibitory effects. Ubiquitin-activating enzyme E1 (100 nM), UBA1, was incubated with 100 mM of each compound prior to
the reaction. (D) E reduces polyubiquitinated forms of Trf1 in a dose-dependent fashion. UBA1 (100 nM) was incubated with either DMSO or various
concentrations of E ranging from 250 mMt o1mM prior to the reaction.
doi:10.1371/journal.pone.0029208.g002
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Uba1p
In addition to ubiquitin, there exist several ubiquitin-like
proteins that covalently modify other proteins. All of the
ubiquitin-like proteins have activation pathways similar to
ubiquitin [38]. In order to study the specificity of Largazole to
the ubiquitin pathway, we incubated Largazole ketone with
SUMO-activating E1 enzyme prior to carrying out a thioester
assay. From the results in Figure 5B, we found that Largazole
ketone is ineffective in inhibiting the formation of E1-SUMO
adducts. From the dose-response curve generated from the SUMO
E1 fluorescence results, the IC50 is approximately 450 mMa s
opposed to 30 mM for ubiquitin E1 (data not shown). Thus
Largazole is relatively selective in perturbing ubiquitin E1
activation.
Ubiquitin and the ubiquitin E1 enzyme are highly conserved
among eukaryotes [38]. Sequence analysis shows a 45% homology
between the human ubiquitin-activating enzyme E1 (UBA1) and
S. pombe E1 (ptr3/Uba1p) at the amino acid sequence level. To test
whether Largazole ketone inhibits the S. pombe E1, we carried out a
thioester assay using Largazole ketone and the ubiquitin E1
homologue in S. pombe, Uba1p. The results in Figure 5A suggest
that Largazole ketone fails to inhibit the formation of E1-ubiquitin
adducts at concentrations less than 1 mM. Taken together, these
results suggest that Largazole and its derivative are highly selective
in inhibiting the ubiquitin E1 enzyme.
Discussion
In this study, we showed that Largazole and its analogs
selectively inhibit ubiquitin E1 enzyme activity in vitro. Also, we
demonstrated that the inhibitory activity of Largazole is
independent of its inhibitory activity towards the histone
deacetylase enzymes. Structure-activity relationship analysis shows
that the thioester bond is not required for inhibition but the
macrocycle core and aliphatic tail are indispensible. Largazole
blocks ubiquitin activation at the adenylation step and without
perturbing ubiquitin transfer from E1 to E2. Finally we show that
Largazole inhibition of E1 is highly selective as it does not inhibit a
highly related ubiquitin E1 enzyme from S. pombe and is almost
twenty fold less effective in inhibiting the activation of SUMO E1.
Taken together, our results reveal that Largazole represents a new
class of ubiquitin E1 inhibitors.
Figure 3. Largazole (L) and largazole ester (E) inhibit ubiquitin E1 in a dose dependent manner in vitro. (A,C) L and E inhibit transfer of
ubiquitin onto E1 in a concentration-dependent manner. Thioester assay of E1 activity using fluorescein ubiquitin (Ub-F). Thioester bond formation
between E1 and Ub-F is ATP-dependent (lane 2 vs. lane 1). In addition, DMSO has no effect on the formation of the thioester linkage as seen in lane 2
of both gels. 50 nM E1 was incubated with decreasing concentrations of L (A) or E (C) for 15 minutes at room temperature followed by addition of a
cocktail containing ATP and Ub-F. After 5 minutes of incubation, the reactions were resolved by SDS-PAGE under non-reducing conditions. Ub-F was
used to show equal loading. (B,D) Thioester assay of the ubiquitin transfer from E1 to E2 (Cdc34). Largazole or Largazole ester, when preincubated
with 50 nM E1 for 15 minutes, inhibit the transfer of ubiquitin from E1 to Cdc34 in a concentration-dependent manner. (E) Largazole selectively
inhibits the activity of E1 not E2. 50 nM E1 was pre-charged with ATP and then added to Cdc34 that was previously incubated with decreasing
concentrations (1 mM–16 mM) of L in thioester reaction mixture. (F) Largazole ester inhibits E2 at high concentrations. Pre-charged E1 was added to
reactions that contained Cdc34 pre-incubated with E ranging from 1 mM to 16 mM and resolved by SDS-PAGE under non-reducing conditions.
Complete inhibition of ubiquitin transfer to E2 was observed at 1 mM of E, with only modest inhibition at 500 mM. (G) Largazole thiol (T) has no effect
on transfer of ubiquitin onto E1. The reaction was carried out as described in A,C.
doi:10.1371/journal.pone.0029208.g003
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p27 expression in Kip16 cells. This observation led us to further
investigate the mechanism of GFP-p27 stabilization by Largazole.
Using an in vitro ubiquitination assay, we were able to delineate the
inhibitory point where Largazole acts on in the ubiquitination
pathway, namely the E1 enzyme. However, there is a disconnect
between the potency of E1 inhibition in vitro and GFP-p27
stabilization in cells. The EC50 of Largazole for GFP-p27
stabilization is in the low nM range, yet E1 inhibition is at
,30 mM. This results suggests that the stabilization of GFP-p27 is
unlikely caused by E1 inhibition, but is most likely a result of
HDAC activity, which is known to block cell cycle progression and
cause cell growth arrest. Consistent with this hypothesis, Largazole
ketone and ester, two Largazole analogs that do not inhibit
HDACs, do not increase GFP-p27 levels when Kip16 cells were
treated (data not shown). However, other interpretations may
account for the failure of Largazole ketone or ester to raise GFP-
p27 by inhibiting E1 in cells. For example, we do not know if or
how these compounds penetrate cells and how stable they are once
they enter the cells. These investigations have to be undertaken
before these analogs can be further developed for in vivo
applications.
Panepophenanthrin, a natural compound derived from the
mushroom strain Panus rudis, and Himeic acid A, derived from the
marine fungus Aspergillus, are the first and second discovered
inhibitors of the ubiquitin-activating enzyme E1, respectively
[39,40]. Both compounds were tested in vitro using recombinant
E1; however, the cellular activity and mechanism were not
determined [41]. PYR-41 and related pyrazones are another set of
compounds that were discovered to inhibit ubiquitin E1 and the
first set of E1 inhibitors described to enter cells and differentially
kill transformed cells [42]. The IC50 of PYR-41 is around 5 mM,
thus more potent than the compounds described here. However,
the exact mechanism of PYR-41 inhibition is not known. Ub-
AMSN represents a distinct class of protein based inhibitors of
ubiquitin E1. Ub-AMSN contains a sulfamide group attached to
the carboxyl terminus of ubiquitin as a nonhydrolyzable mimic of
the phosphate group in the cognate Ub/Ubl-AMP adenylate
intermediate. Thus, like Largazole analogs, it blocks the first step
of E1 reaction [43,44]. Unfortunately, Ub-AMSN cannot be used
in cells as it cannot pass through the cell membrane. However,
Ub-AMSN turns out be a very useful for probing the structure and
biochemical mechanisms of E1 enzyme [44]. Therefore, Largazole
and analogs could also be useful tools for probing ubiquitin
function.
One of the most important questions to be answered is whether
or not ubiquitin or ubiquitin-like E1 inhibitors are therapeutically
relevant. Since only one ubiquitin E1 enzyme is responsible for a
majority of protein ubiquitination in humans, inhibiting E1 will
influence the degradation of proteins across several pathways and
may lead to toxicity and, consequently, poor therapeutic efficacy.
Bortezomib is the first FDA-approved proteasome inhibitor for the
treatment of relapsed/refractory myeloma and mantle cell
lymphoma. [19]. The proteasome, particularly the 26S protea-
some, is the final step in ubiquitin-mediated protein degradation
and regulates various pathways necessary for cellular function.
The clinical success and efficacy of Bortezomib gives rise to the
possibility that inhibitors of ubiquitin E1 will also share similar
success. NEDD8 is a protein modifier that shares mechanistic and
structural similarities to ubiquitin. Currently, the cullin family of
Figure 4. Largazole ketone inhibits the adenylation of the E1
ubiquitin-activating enzyme. (A) Largazole ketone inhibits ligation
of ubiquitin onto E1 in a concentration-dependent fashion. Reduction
of E1,Ub adducts was determined by thioester assay utilizing
fluorescein ubiquitin. (B) Largazole ketone inhibits the adenylation
step in ubiquitin E1 activation in a concentration-dependent fashion. K
was serially diluted (100 mM to 1.5 mM) and incubated with UBA1
(150 nM) at room temperature for five minutes. The thioester reaction
mixture was mixed with ubiquitin to initiate the PPi:ATP exchange
(middle panel) or AMP:ATP exchange (bottom panel) and added to the
UBA1/K mixture. All reactions were halted with addition of EDTA after
10 minute incubation at 37uC, resolved using Cellulose PEI TLC plates,
and analyzed using a phosphoimager.
doi:10.1371/journal.pone.0029208.g004
Figure 5. Investigation into the selectivity of Largazole ketone.
(A) Largazole ketone (K) fails to inhibit the ligation of ubiquitin onto
Uba1p, a homologue of UBA1 from S. pombe. Formation of Uba1p-
ubiquitin adducts was determined by thioester assay utilizing
fluorescein-ubiquitin. Uba1p (1.03 mM) was incubated with either
DMSO or various concentrations of K serially diluted from 1000 mMt o
31 mM. (B) K inhibits ligation of SUMO-1 onto human SUMO E1 in a
concentration-dependent fashion. Reduction of E1-SUMO adducts was
determined by thioester assay utilizing fluorescein-SUMO-1. hSUMO E1
(500 nM) was incubated with either DMSO or various concentrations of
K serially diluted from 1000 mMt o3 1mM.
doi:10.1371/journal.pone.0029208.g005
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conjugation [11]. MLN4924 is a potent and selective inhibitor
of the NEDD8-activating enzyme (NAE) that exhibited potent
cytotoxicity against several human tumor-derived cell lines [45].
Interestingly, MLN4924 shares a similar mechanism to Largazole
analogs. MLN4924 reacts covalently with NEDD8 mimicking a
NEDD8 adenylate that is incapable of driving the reaction
forward, therefore, blocking the activity of NAE [46]. MLN4924 is
currently undergoing phase I clinical trials in patients with
lymphoma, multiple myeloma, or any form of nonhematologic
malignancies. The in vitro and possible clinical success of the NAE
inhibitor MLN4924 further supports the concept that E1
inhibitors are potential promising cancer therapeutics.
Our preliminary structure activity relationship studies suggest
that the pro-drug form of Largazole including both the
hydrocarbon tail and the macrocycle are essential for E1
inhibition. For Largazole analogs to be developed as potential
antitumor drugs, additional analogs are needed to be synthesized
in order to improve its potency toward ubiquitin E1. The most
promising aspect of Largazole analogs as ubiquitin E1 inhibitors is
the selectivity and specificity of Largazole. Largazole analogs not
only display discrimination over related SUMO E1 enzyme but
also remarkable selectivity in targeting human ubiquitin E1.
Future structural studies would be helpful to understand how
Largazole analogs inhibit E1, and insights gained from such
studies may help to develop more specific inhibitors of E1.
Experiments to test these hypotheses are currently underway.
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